Zobrazeno 1 - 10
of 175
pro vyhledávání: '"Deborah A, Dillon"'
Autor:
Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tolaney, Nancy U. Lin, Deborah A. Dillon, Stuart J. Schnitt, Peter K. Sorger, Elizabeth A. Mittendorf, Sandro Santagata
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-22 (2024)
Abstract Emerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with therapy resistance, highlighting the need for new strategies to assess HER2 ITH. A promising approach is leveraging multiplexed tissue analysis techniques s
Externí odkaz:
https://doaj.org/article/3efb1bd4ddfe4838842869755c17c107
Autor:
Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar K. Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang, Jason J. Zoeller, Hye-Jung Kim, Thomas M. Roberts, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Deborah A. Dillon, Eric P. Winer, Nancy U. Lin, Jean J. Zhao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
PARP inhibitor (PARPi) therapy has demonstrated only modest efficacy in advanced breast cancer with BRCA mutations. Here the authors show that, by suppressing PARPi-triggered DNA damage and reducing dsDNA production in BRCA1-deficient breast tumor ce
Externí odkaz:
https://doaj.org/article/6187b06c5a3643429f9e40f41b6a7bb5
Autor:
Yasha Ektefaie, William Yuan, Deborah A. Dillon, Nancy U. Lin, Jeffrey A. Golden, Isaac S. Kohane, Kun-Hsing Yu
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract Histopathologic evaluation of biopsy slides is a critical step in diagnosing and subtyping breast cancers. However, the connections between histology and multi-omics status have never been systematically explored or interpreted. We developed
Externí odkaz:
https://doaj.org/article/0054a716bf894cfeb760d0ff078ec507
Autor:
Sankha S. Basu, Sylwia A. Stopka, Walid M. Abdelmoula, Elizabeth C. Randall, Begoña Gimenez-Cassina Lopez, Michael S. Regan, David Calligaris, Fake F. Lu, Isaiah Norton, Melissa A. Mallory, Sandro Santagata, Deborah A. Dillon, Mehra Golshan, Nathalie Y. R. Agar
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Optimal resection of breast tumors requires removing cancer with a rim of normal tissue while preserving uninvolved regions of the breast. Surgical and pathological techniques that permit rapid molecular characterization of tissue could faci
Externí odkaz:
https://doaj.org/article/6971c3e8117e459bae7cdcea6a03c082
Autor:
Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniels, Krishan Taneja, Benjamin Y. Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony Letai, Joel D. Leverson, Vincent Blot, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-13 (2020)
Abstract Background Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of these studies was to
Externí odkaz:
https://doaj.org/article/7961025b271046ca91a4d856080ab647
Autor:
Paolo Tarantino, Hersh V. Gupta, Melissa E. Hughes, Janet L. Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Y. Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany Bychkovsky, Laura MacConaill, Neal Lindeman, Bruce Johnson, Matthew Meyerson, Sheheryar Kabraji, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry W. Long, Eric Winer, Deborah A. Dillon, Giuseppe Curigliano, Andrew Cherniack, Sara Tolaney, Nancy U. Lin
Publikováno v:
Cancer Research. 83:HER2-05
Background: About half of all breast cancers exhibit low HER2 expression. Despite lack of ERBB2 amplification, HER2-low tumors respond to trastuzumab deruxtecan (T-DXd), leading to the NCCN recommendation of T-DXd both for patients with HER2+ and HER
Autor:
Lior Z. Braunstein, Julia Wong, Deborah A. Dillon, Yu-Hui Chen, Paul Catalano, Oren Cahlon, Mahmoud B. El-Tamer, Rachel Jimenez, Atif Khan, Carmen Perez, Rinaa Punglia, Ron Shiloh, Laura Warren, David Wazer, Jean Wright, Elizabeth Buckley, Tari King, Simon Powell, Eric Winer, Jennifer Bellon
Publikováno v:
Cancer Research. 83:OT1-12
Background: Breast conserving surgery (BCS) is typically followed by adjuvant radiotherapy (RT) based on several landmark trials demonstrating improvements in disease control and survival. Since completion of these historical trials, the advent of mo
Autor:
Hersh V. Gupta, Rachel Freedman, Melissa E. Hughes, Yvonne Y. Li, Gregory Kirkner, Janet L. Files, Sarah Strauss, Ana C. Garrido-Castro, Lauren Buckley, Romualdo Barroso-Sousa, Brittany Bychkovsky, Sara Tolaney, Laura MacConaill, Neal Lindeman, Bruce Johnson, Matthew Meyerson, Eric Winer, Deborah A. Dillon, Andrew Cherniack, Nancy U. Lin
Publikováno v:
Cancer Research. 83:P5-14
Background. Patients (pts) who develop MBC at older ages are underrepresented in clinical trials, are less likely to be included in comprehensive biomarker characterization studies, and experience worse breast cancer-specific survival than their youn
Autor:
Tabata Alves Domingos, Roberto Bonfim Pimenta Peixoto, Ashka Patel, Krishan Taneja, Wendy Y. Chen, Elizabeth A. Mittendorf, Alexa Zimbalist, Elizabeth M. Cespedes Feliciano, Deborah A. Dillon
Publikováno v:
Cancer Research. 83:P4-09
Correlation between histology and molecular subtypes in triple negative breast cancer Authors: Tabata Alves Domingos, MD; 1* Roberto Bonfim Pimenta Peixoto, MD; 1* Ashka Patel, BS1,2; Krishan Taneja, PhD; 1 Wendy Y. Chen, MD, MPH; 4,5,6 Elizabeth A.
Autor:
Kornelia Polyak, Senthil K. Muthuswamy, Deborah A. Dillon, Gordon J. Freeman, Sara M. Tolaney, Eliezer M. Van Allen, Tanya E. Keenan, Katherine C. Murphy, Bethlehem Lulseged, Ethan D. Krop, Shanshan Xie, Michael U.J. Oliphant, Nicholas W. Harper, Ernesto Rojas Jimenez, Maša Alečković, Anne Trinh, Carlos R. Gil Del Alcazar
Supplementary Figure from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b3e63f003b1e1eafb910ef2ba844d94
https://doi.org/10.1158/2326-6066.22544781
https://doi.org/10.1158/2326-6066.22544781